<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02292303</url>
  </required_header>
  <id_info>
    <org_study_id>BTS812/14</org_study_id>
    <nct_id>NCT02292303</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Determine the Bioavailability of Three Different Zinc Preparations</brief_title>
  <official_title>Randomized, Monocentric, Double-blind, 3-way-cross-over Clinical Trial to Determine the Bioavailability of Three Different Zinc Preparations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lesaffre International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lesaffre International</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this clinical is to get information on pharmacokinetics of&#xD;
      zinc-enriched yeast.The bioavailability of the yeast enriched with zinc will be compared to&#xD;
      two selected zinc salts used in food supplements that are zinc oxide and zinc gluconate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of pharmacokinetics parameters (AUC, Cmax and Tmax) between zinc-enriched yeast and zinc oxide.</measure>
    <time_frame>Baseline (0 min); 30; 60; 90;120; 150; 180; 210; 240; 300 and 360 min</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of pharmacokinetics parameters (AUC, Cmax and Tmax) between zinc-enriched yeast and zinc gluconate.</measure>
    <time_frame>Baseline (0 min); 30; 60; 90;120; 150; 180; 210; 240; 300 and 360 min</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Zinc Deficiency</condition>
  <arm_group>
    <arm_group_label>zinc-enriched yeast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>zinc-enriched yeast capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>zinc oxide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>zinc oxide capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>zinc gluconate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>zinc gluconate capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>zinc-enriched yeast</intervention_name>
    <arm_group_label>zinc-enriched yeast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc references</intervention_name>
    <arm_group_label>zinc gluconate</arm_group_label>
    <arm_group_label>zinc oxide</arm_group_label>
    <other_name>zinc oxide; zinc gluconate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is able and willing to sign the Informed Consent Form prior to screening&#xD;
             evaluations&#xD;
&#xD;
          -  Sex: female (premenopausal), male&#xD;
&#xD;
          -  Age: 20 - 50 years&#xD;
&#xD;
          -  BMI ≥19 or ≤30 kg/m²&#xD;
&#xD;
          -  Non-smoker&#xD;
&#xD;
          -  Subject is in good physical and mental health as established by medical history,&#xD;
             physical examination, electrocardiogram, vital signs, results of biochemistry,&#xD;
             hematology&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Relevant history or presence of any medical disorder, potentially interfering with&#xD;
             this trial&#xD;
&#xD;
          -  For this trial clinically relevant abnormal laboratory, ECG, vital signs or physical&#xD;
             findings at screening&#xD;
&#xD;
          -  Migraine or regular headache, intense premenstrual symptoms&#xD;
&#xD;
          -  Coffee consumption &gt;3 cups / day&#xD;
&#xD;
          -  Blood donation within 2 months prior to trial start or during trial&#xD;
&#xD;
          -  Regular intake of mineral supplements within 4 weeks prior to trial start or during&#xD;
             trial&#xD;
&#xD;
          -  Chronic intake of substances affecting the intestinal absorption of zinc&#xD;
&#xD;
          -  Vegetarians / vegans&#xD;
&#xD;
          -  Drug-, alcohol- and medication abuses&#xD;
&#xD;
          -  Known HIV-infection&#xD;
&#xD;
          -  Known acute or chronic hepatitis B and C infection&#xD;
&#xD;
          -  Relevant allergy or known hypersensitivity against compounds of the study&#xD;
             preparations, for example lactose intolerance&#xD;
&#xD;
          -  Known pregnancy, breast feeding or intention to become pregnant during the study&#xD;
&#xD;
          -  Participation in another clinical trial within the last 4 weeks and concurrent&#xD;
             participation in another clinical trial&#xD;
&#xD;
          -  Not anticipating any planned changes in lifestyle for the duration of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>November 7, 2014</study_first_submitted>
  <study_first_submitted_qc>November 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2014</study_first_posted>
  <last_update_submitted>June 11, 2018</last_update_submitted>
  <last_update_submitted_qc>June 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Zinc/pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zinc</mesh_term>
    <mesh_term>Zinc Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

